Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Beginning Cash Balance: 2009-2024

Historic Beginning Cash Balance for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $221.1 million.

  • Ani Pharmaceuticals' Beginning Cash Balance fell 9.28% to $217.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year decrease of 24.90%. This contributed to the annual value of $221.1 million for FY2024, which is 315.31% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Beginning Cash Balance of $221.1 million as of FY2024, which was up 315.31% from $53.2 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Beginning Cash Balance registered a high of $221.1 million during FY2024, and its lowest value of $7.9 million during FY2021.
  • Moreover, its 3-year median value for Beginning Cash Balance was $100.3 million (2022), whereas its average is $124.9 million.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first slumped by 87.39% in 2021, then skyrocketed by 1,175.04% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Beginning Cash Balance (Yearly) stood at $62.4 million in 2020, then crashed by 87.39% to $7.9 million in 2021, then soared by 1,175.04% to $100.3 million in 2022, then slumped by 46.92% to $53.2 million in 2023, then spiked by 315.31% to $221.1 million in 2024.